Calgarypuck Forums - The Unofficial Calgary Flames Fan Community - View Single Post

troutman · 10-26-2009, 03:18 PM

http://www.sciencebasedmedicine.org/?p=2255

For those who battle tirelessly against the never ending onslaught of anti-vaccine propaganda, misinformation, and fear, there was great news the other day from Merck. The pharmaceutical company, and maker of the MMR vaccine against measles, mumps, and rubella, has decided not to resume production of the individual, or “split”, components of the vaccine.

this decision is a vote against irrationality and an anti-scientific worldview that has begun to endanger society. Many parents will be upset and disappointed by Merck’s decision, especially those who were just recently reassured by Dr. Sears that Merck was poised to reintroduce the separate components in 2011. The fact is, this was actually a bad decision for Merck from a purely economic perspective. It costs considerably more to manufacture, produce, and test combination vaccines than monovalent vaccines. Selling three individual components would also produce more revenue than a single combination product.

10-26-2009, 03:18 PM	#261
troutman Unfrozen Caveman Lawyer Join Date: Oct 2002 Location: Crowsnest Pass Exp:	http://www.sciencebasedmedicine.org/?p=2255 For those who battle tirelessly against the never ending onslaught of anti-vaccine propaganda, misinformation, and fear, there was great news the other day from Merck. The pharmaceutical company, and maker of the MMR vaccine against measles, mumps, and rubella, has decided not to resume production of the individual, or “split”, components of the vaccine. this decision is a vote against irrationality and an anti-scientific worldview that has begun to endanger society. Many parents will be upset and disappointed by Merck’s decision, especially those who were just recently reassured by Dr. Sears that Merck was poised to reintroduce the separate components in 2011. The fact is, this was actually a bad decision for Merck from a purely economic perspective. It costs considerably more to manufacture, produce, and test combination vaccines than monovalent vaccines. Selling three individual components would also produce more revenue than a single combination product.